Peptides and pharmaceutical compositions comprising same
The present invention relates to an NST500 compound of general formula (I): comprising the following components: X 1 —X 2 —{(X 3 ) a /X 4 /X 5 }—X 6 , wherein: X 1 stands for a saturated or unsaturated fatty acid residue comprising 6–20 carbon atoms; or a cysteine residue bound through a thioether bond to a prenyl group comprising 5–20 carbon atoms; said residue being linked to the adjacent component of the compound through an amide bond; X 2 is 0; X 3 comprises 1–6 amino acids, of which 1–6 are positively charged and 0–2 are negatively charged, the other amino acid residues being polar uncharged amino acids; X 4 comprises 1–6 amino acids, of which 1–2 are aromatic amino acids, the other amino acids being selected among polar uncharged amino acids and hydrophobic aliphatic amino acids; X 5 comprises 6–8 amino acids, of which 4–6 are positively charged and 0–2 are negatively charged, the other amino acid residues being polar uncharged amino acids, wherein the amino acids form a cyclic structure; X 6 is a compound of general formula II, wherein Z stands for a spacer group selected among alkane and alkene containing 1–5 carbon atoms, J stands for a functional group selected among amines, thiols, alcohols, carboxylic acids and esters, aldehydes and alkyl halides; U is 0 or is selected among a labeling group; wherein a stands for an integer of 1–3; and the groups X 3 , X 4 and X 5 being located at various places in the compound; as well as functional equivalents thereof and/or compounds having the same biological activity thereto. The present also relates to pharmaceutical compositions and methods of using the same.
1. A compound of general formula I comprising the following components:
X 1 —X 2 —{(X 3 ) a /X 4 /X 5 }—X 6
wherein:
X 1 stands for a saturated or unsaturated fatty acid residue comprising 14 carbon atoms;
X 2 is 0;
X 3 consists of 1–2 positively charged amino acids;
X 4 consists of 4 amino acids, of which 2 are aromatic amino acids, 1 is a polar uncharged amino acids and 1 is a hydrophobic aliphatic amino acids;
X 5 consists of 8 amino acids, of which 4–5 are positively charged and 0–1 is negatively charged, 2 amino acid residues being polar uncharged amino acids, wherein the 2 amino acid residues form a cyclic structure and 1 polar uncharged amino acid;
wherein the groups X 3 , X 4 and X 5 being located at various places in the compound;
X 6 is a compound of general formula II
wherein Z stands for a spacer group selected from the group consisting of alkane and alkene containing 1–5 carbon atoms, J stands for a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters, aldehydes and alkyl halides; U is 0 or a labeling group for specific binding selected from the group consisting of biotin and a group containing a substituent selected from the group consisting of a fluorescein, a radioisotope and a paramagnetic contrast agent;
wherein:
a stands for an integer of 1–2.
2. The compound according to claim 1 , wherein X 1 is a myristic acid.
3. The compound according to claim 1 , wherein the positively charged amino acids of X 3 and X 5 are selected from the group consisting of lysine, arginine, histidine and combinations thereof.
4. The compound according to claim 3 , wherein the positively charged amino acids of X 3 and X 5 are selected from the group consisting of lysine, arginine and combinations thereof.
5. The compound according to claim 1 wherein the negatively charged amino acids of X 5 are selected from the group consisting of glutamate and aspartate.
6. The compound according to claim 1 wherein the polar uncharged amino acids of X 5 are selected from the group consisting of serine, threonine, asparagine, glutamine and combinations thereof.
7. The compound according to claim 1 , wherein the aromatic acids of X 4 are selected from the group consisting of phenylalanine, tryptophan and combinations thereof.
8. The compound according to claim 1 , wherein the polar uncharged amino acid of X 4 is selected from the group consisting of serine, asparagine, glutamine and combinations thereof.
9. The compound according to claim 1 , wherein the hydrophobic aliphatic amino acid of X 4 is selected from the group consisting of leucine, valine, alanine, glycine and combinations thereof.
10. The compound according to claim 1 , wherein cyclization of X 5 is performed via an intra-molecular disulfide bridge or by an amide bond or via a bond to 99 Tc.
11. The compound according to claim 1 , wherein the fluorescein is fluorescein isothiocyanate.
12. The compound according to claim 1 , wherein the radioisotope is selected from the group consisting of technetium, lead, mercury, thallium and indium.
13. The compound according to claim 1 , wherein the paramagnetic contrast agent is a paramagnetic metal ion chelate gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA).
14. The compound according to claim 1 , wherein X 6 is a lysine residue being substituted at an e-amino group by a labeling group.
15. The compound according to claim 1 , wherein X 6 stands for a cysteine residue bound through a thioether bond to a prenyl group, in which the cysteine carboxyl group is either free or methylated.
16. Myristate-KVSFFCKNKEKKC-K (SEQ ID NO:1)U, wherein U is as defined in claim 1 .
17. Myristate-KVSFFCKNKEKKC-K(SEQ ID NO:1) (biotin) in which the two cystein residues are linked via a disulfide bond, to form a cyclic structure.
18. Myristate-KKVFSFCKNKEKKC-K(SEQ ID NO:2)U, wherein U is as defined in claim 1 .
19. Myristate-KKVFSFCKNKEKKC-K(SEQ ID NO:2) (biotin) wherein the two cystein residues are linked together.
20. A pharmaceutical composition comprising as active ingredient the compound according to any one of claims 1 to 15 .
21. A pharmaceutical composition comprising as active ingredient the compound according to claim 1 , which comprises in addition to the NST500 compound a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising as active ingredient the compound according to claim 21 , wherein the carrier is selected from the group consisting of suitable solvents; emulgators; excipients; and talc.
23. A pharmaceutical composition comprising as active ingredient the compound according to claim 1 which is selected from the group consisting of tablets, capsules, solutions, and emulsions.
24. A pharmaceutical composition comprising as active ingredient the compound according to claim 1 comprising an additional pharmaceutically active compound.
25. A diagnostic kit comprising the compound according to claim 1 .
26. A process for the preparation of the compound of the general formula 1 according to claim 1 comprising the following steps:
a. an orthogonally protected diaminoacid is loaded on a solid support, the ω-amino protecting group is then removed, thereafter a compound comprising substituent U being a labeling agent and not standing for 0 is introduced into amino acid resin in the presence of a coupling reagent and a base, or by using a pre-activation method, then removing the α-amino protecting group of the N-terminal amino acid and the peptide being prepared sequentially on the solid support; and, optionally
b. a substituent X 1 is introduced into the peptide-resin under similar conditions to those used during the coupling of the amino acids in step a, and then the peptide is cleaved from the solid support.
27. A process according to claim 26 , wherein a cyclization of the peptide is performed via an intramolecular di-sulphide bridge by iodine treatment, removal of S-Acm protecting groups on the residues with mercury acetate followed by air oxidation, or by simultaneous de-protection/oxidation with TI(TFA) 3 .
28. A process according to claim 26 wherein the cyclization is performed via a coordination bond to a metal.
29. A process according to claim 26 , wherein a branched 4-multivalent peptide is prepared in that the fatty acid is coupled to A—Y 2 , wherein Y is a protecting group of the carboxyl group, the Y protecting group being then removed and the fatty acid-A being coupled with two equivalents of A—Y 2 , the Y group being then removed and the skeleton obtained being then coupled with a protected peptide prepared on a solid support the final skeleton peptide being purified, lyophilized and characterized by HPLC/MS.
30. A process according to claim 26 or 29 , wherein a branched 8-multivalent peptide is prepared in that the fatty acid
is then coupled with two equivalents of A—(Y) 2 and then the Y protecting groups are removed, the skeleton then being coupled with four equivalents of A—(Y) 2 and the process being continued octavalent peptide.